PDCD1 and non-small cell lung carcinoma: This integrative study combining structural modeling, molecular interaction analysis, and transcriptomic validation confirms EGFR, ALK, KRAS, and PD-1 supports their relevance as clinically actionable and structurally druggable biomarkers in NSCLC.